TriSalus Life Sciences, Inc. (TLSI): who owns it and who trades it
As of Nov 16, 2026, TLSI insiders reported 18 open-market sales worth $140K and 12 purchases worth $3.6M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mary T Szela (CEO), with $79.4K. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling TriSalus Life Sciences
From the latest filingsOverall: more buying than selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns TLSI
79 funds and institutions reported TLSI shares worth $104M at the end of Q2 2026, about 37% of the company. The largest holder is First Light Asset Management, LLC with 10.7%.
Funds and institutions (13F) 37%Everyone else 63%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| First Light Asset Management, LLC | 6.55M | 10.69% | $29.8M | +29% |
| BlackRock, Inc. | 2.66M | 4.34% | $12.1M | +77% |
| Nantahala Capital Management, LLC | 2.00M | 3.26% | $9.1M | -3% |
| Vanguard Capital Management LLC | 1.73M | 2.82% | $7.9M | +28% |
| Cerity Partners LLC | 1.60M | 2.62% | $7.3M | +104% |
| Geode Capital Management, LLC | 1.19M | 1.94% | $5.4M | +53% |
| Gilder Gagnon Howe & Co LLC | 850,081 | 1.39% | $3.9M | -4% |
| State Street Corp | 610,963 | 1.00% | $2.8M | +86% |
| White Pine Capital LLC | 547,577 | 0.89% | $2.5M | +234% |
| Thompson Siegel & Walmsley LLC | 536,534 | 0.88% | $2.4M | -8% |
| Kennedy Capital Management LLC | 476,261 | 0.78% | $2.2M | -2% |
| Morgan Stanley | 401,814 | 0.66% | $1.8M | +2% |
| Northern Trust Corp | 379,572 | 0.62% | $1.7M | +71% |
| Vanguard Portfolio Management LLC | 329,464 | 0.54% | $1.5M | +100% |
| Vanguard Fiduciary Trust Co | 320,956 | 0.52% | $1.5M | +47% |
| Lionhunter Capital Management, LLC | 300,275 | 0.49% | $1.4M | New |
| Perkins Capital Management Inc | 235,101 | 0.38% | $1.1M | +2% |
| UBS Group AG | 223,047 | 0.36% | $1M | +180% |
| Bank of America Corp | 205,342 | 0.33% | $934K | +2% |
| Royce & Associates LP | 200,060 | 0.33% | $910K | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, TLSI insiders reported $3.6M of open-market purchases and $140K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Mats Wahlstrom | Director | Purchase | 50,000 | $2.24 | $112K | Form 4 |
| Oct 5, 2026 | Bryan F. Cox | Chief of Research | Sale | 296 | $4.39 | $1.3K | Form 4 |
| Oct 5, 2026 | Richard Marshak | Chief Commercial Officer | Sale | 325 | $4.39 | $1.4K | Form 4 |
| Oct 5, 2026 | Jennifer Stevens | Chief Regulatory Officer | Sale | 316 | $4.39 | $1.4K | Form 4 |
| May 15, 2026 | Richard Marshak | Chief Commercial Officer | Sale | 543 | $2.67 | $1.4K | Form 4 |
| May 15, 2026 | Mats Wahlstrom | Director | Purchase | 60,000 | $2.53 | $152K | Form 4 |
| May 15, 2026 | Michael P Stansky | Director | Purchase | 410,000 | $2.50 | $1M | Form 4 |
| May 15, 2026 | Michael P Stansky | Director | Purchase | 200,000 | $2.50 | $500K | Form 4 |
| May 15, 2026 | Mary T Szela | CEO | Purchase | 39,682 | $2.59 | $103K | Form 4 |
| May 15, 2026 | David Patience | CFO | Purchase | 7,100 | $2.43 | $17.3K | Form 4 |
| May 15, 2026 | Gary B. Gordon | Director | Purchase | 10,000 | $2.46 | $24.6K | Form 4 |
| Mar 17, 2026 | Mary T Szela | CEO | Sale | 15,944 | $3.85 | $61.4K | Form 4 |
| Mar 16, 2026 | Jodi Devlin | Chief of Clinical Operat | Sale | 273 | $4.12 | $1.1K | Form 4 |
| Mar 16, 2026 | Bryan F. Cox | Chief of Research | Sale | 579 | $4.12 | $2.4K | Form 4 |
| Mar 16, 2026 | Richard Marshak | Chief Commercial Officer | Sale | 419 | $4.12 | $1.7K | Form 4 |
| Mar 16, 2026 | Jennifer Stevens | Chief Regulatory Officer | Sale | 774 | $4.12 | $3.2K | Form 4 |
| Mar 12, 2026 | Jodi Devlin | Chief of Clinical Operat | Sale | 1,772 | $4.09 | $7.2K | Form 4 |
| Mar 12, 2026 | Bryan F. Cox | Chief of Research | Sale | 1,467 | $4.09 | $6K | Form 4 |
| Mar 12, 2026 | Richard Marshak | Chief Commercial Officer | Sale | 1,589 | $4.09 | $6.5K | Form 4 |
| Mar 12, 2026 | Jennifer Stevens | Chief Regulatory Officer | Sale | 1,552 | $4.09 | $6.3K | Form 4 |
| Mar 11, 2026 | Jodi Devlin | Chief of Clinical Operat | Sale | 1,162 | $4.13 | $4.8K | Form 4 |
| Mar 11, 2026 | Bryan F. Cox | Chief of Research | Sale | 1,138 | $4.13 | $4.7K | Form 4 |
| Mar 11, 2026 | Richard Marshak | Chief Commercial Officer | Sale | 1,449 | $4.13 | $6K | Form 4 |
| Mar 11, 2026 | Jennifer Stevens | Chief Regulatory Officer | Sale | 1,204 | $4.13 | $5K | Form 4 |
| Mar 11, 2026 | Mary T Szela | CEO | Sale | 4,358 | $4.13 | $18K | Form 4 |
| Feb 23, 2026 | David Patience | CFO | Purchase | 3,657 | $4.10 | $15K | Form 4 |
| Feb 23, 2026 | Gary B. Gordon | Director | Purchase | 9,756 | $4.10 | $40K | Form 4 |
| Feb 23, 2026 | William Valle | Director | Purchase | 30,487 | $4.10 | $125K | Form 4 |
| Feb 23, 2026 | Michael P Stansky | Director | Purchase | 243,900 | $4.10 | $1000K | Form 4 |
| Feb 23, 2026 | Michael P Stansky | Director | Purchase | 117,198 | $4.10 | $481K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Michael P Stansky | Director | $3M | – | May 15, 2026 |
| Mats Wahlstrom | Director | $264K | – | Nov 12, 2026 |
| Mary T Szela | CEO and President, Director | $103K | $79.4K | May 15, 2026 |
| William Valle | Director | $125K | – | Feb 23, 2026 |
| Gary B. Gordon | Director | $64.6K | – | May 15, 2026 |
| David Patience | Chief Financial Officer | $32.2K | – | May 15, 2026 |
| Richard Marshak | Chief Commercial Officer | – | $17.1K | Oct 5, 2026 |
| Jennifer Stevens | Chief Regulatory Officer | – | $15.9K | Oct 5, 2026 |
| Bryan F. Cox | Chief of Research | – | $14.4K | Oct 5, 2026 |
| Jodi Devlin | Chief of Clinical Operations | – | $13.2K | Mar 16, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TLSI short interest
Moderate short interest. 5.4% of TLSI shares are sold short: about 1 share in 19. Over the last 12 reports the number of shares short went up 97%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.31M TLSI shares were sold short, 5.4% of the shares outstanding, down 3.8% from the report before. At the average daily volume of 116,423 shares, buying them all back would take about 28.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.31M | 5.38% | -4% | 116,423 | 28.4 |
| Oct 15, 2026 | 3.44M | 5.59% | +3% | 171,292 | 20.1 |
| Sep 30, 2026 | 3.35M | 5.44% | No change | 759,590 | 4.4 |
| Sep 15, 2026 | 3.35M | 5.43% | -9% | 116,107 | 28.8 |
| Aug 31, 2026 | 3.69M | 6.00% | -3% | 102,902 | 35.9 |
| Aug 14, 2026 | 3.79M | 6.16% | +0% | 270,685 | 14.0 |
| Jul 31, 2026 | 3.77M | 6.15% | +6% | 170,370 | 22.1 |
| Jul 15, 2026 | 3.56M | 5.81% | +16% | 276,782 | 12.9 |
| Jun 30, 2026 | 3.08M | 5.02% | +41% | 678,939 | 4.5 |
| Jun 15, 2026 | 2.19M | 3.57% | +4% | 323,879 | 6.8 |
| May 29, 2026 | 2.10M | 3.43% | +25% | 428,237 | 4.9 |
| May 15, 2026 | 1.69M | 2.75% | +17% | 1.02M | 1.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
TriSalus Life Sciences company events
TriSalus Life Sciences filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Sep 22, 2026AnnouncementTriSalus Life Sciences, Inc. issued a press release announcing that it has received U.S. Food and Drug Administration 510(k) clearance for its TriNav Advance device. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- May 14, 2026VoteReported shareholder vote results. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Apr 29, 2026LeadershipJodi Devlin provided notice to TriSalus Life Sciences, Inc. of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026. Filing
- Apr 7, 2026LeadershipTriSalus Life Sciences, Inc. entered into an offer letter with Dr. Richard Marshall for the position of Chief Medical Officer. Filing
- Mar 5, 2026ResultsReleased financial results. Filing
- Feb 20, 2026AgreementTriSalus Life Sciences, Inc. entered into an underwriting agreement with Lake Street Capital Markets, LLC, as representative of the underwriters named therein, relating to the public offering of 9,756,100 shares of common stock of the Company, par value $0.0001 per share, at a price to the public… Filing
- Feb 9, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
TriSalus Life Sciences financials
Famous investors that hold TLSI
1 of the 50 well-known investors we track reported holding TLSI in their latest 13F filing. The largest position is Israel Englander's, worth $156K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 36,140 | $156K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named TLSI in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | First Light Asset Management, LLC | 13G/A | 12.0% |
| Nov 16, 2026 | First Light Asset Management, LLC | 13G/A | 12.0% |
Questions about TriSalus Life Sciences, Inc. (TLSI) stock
Who owns the most TLSI stock?
The largest reported owner of TriSalus Life Sciences, Inc. (TLSI) is First Light Asset Management, LLC, with 10.7% of the company. In total, 79 funds and institutions reported holding TLSI at the end of Q2 2026, together about 37% of the shares. See the largest owners.
Are TLSI insiders buying or selling?
In the last 12 months, TLSI insiders reported 12 open-market purchases worth $3.6M and 18 sales worth $140K. The latest trade was on Nov 12, 2026. See every trade.
What is the short interest in TLSI?
As of Oct 30, 2026, 3.31M TLSI shares were sold short, 5.4% of the shares outstanding, down 3.8% from the report before. At the average daily volume of 116,423 shares, buying them all back would take about 28.4 trading days (days to cover). See the history.
Which famous investors hold TLSI?
1 of the 50 well-known investors we track reported TLSI in their latest 13F filing, including Israel Englander. The largest position is worth $156K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.